<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537132</url>
  </required_header>
  <id_info>
    <org_study_id>FDG_ALS1H_01</org_study_id>
    <nct_id>NCT02537132</nct_id>
  </id_info>
  <brief_title>&quot;New Perspectives of Adaptation to NIV in ALS&quot;</brief_title>
  <official_title>&quot;New Perspectives of Adaptation to Non-Invasive Ventilation (NIV) in Amyotrophic Lateral Sclerosis (ALS)&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Don Carlo Gnocchi Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Don Carlo Gnocchi Onlus</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the adaptation to the Non Invasive
      Ventilation (NIV) at home is not worse when compared with an adaptation performed in
      inpatient settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date>January 2018</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in adherence NIV in ALS patients at baseline, 2 and 4 months as measured by monthly means and standard deviations of hours of use of Non Invasive Ventilation (NIV)</measure>
    <time_frame>Baseline + after 2 and 4 months from the recruitment</time_frame>
    <description>The primary outcome the time of adherence to NIV defined as actual use of NIV for not less than 150 hours / month.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Home Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at home</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatient Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at the outpatient clinic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adaptation and training to Non Invasive Ventilation (NIV)</intervention_name>
    <description>Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.</description>
    <arm_group_label>Home Group</arm_group_label>
    <arm_group_label>Outpatient Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALS diagnosis according to the criteria of El Escorial;

          -  Clinical indication to NIV (nocturnal hypoventilation and respiratory muscle weakness
             confirmed according to the criteria normally accepted);

          -  No respiratory infection within 3 months

          -  Severe disability (ALS-FRS &lt;31);

          -  Age &gt; 18 years;

          -  The voluntary participation to the Study.

        Exclusion Criteria:

        -- Previous episodes of pneumothorax;

          -  Comorbid cardiac and / or renal important

          -  Severe cognitive impairment;

          -  Refusal of the patient at the time of Informed Consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Michele Vitacca</name>
      <address>
        <city>Lumezzane</city>
        <state>Brescia</state>
        <zip>25065</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paolo Banfi</name>
      <address>
        <city>Milan</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Invasive Ventilation (NIV)</keyword>
  <keyword>Amyotrophic Lateral sclerosis (ALS)</keyword>
  <keyword>adaptation</keyword>
  <keyword>home care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

